Back to Authors

Oyeleke, Ganiyat K.

https://orcid.org/0000-0002-8089-7609

Mayo Clinic

University of Lagos

Citations 3

Circulating cell‐free DNA methylation biomarkers for hepatocellular carcinoma risk prediction in HIV ‐positive Nigerian population
Zheng, Yinan , Han, Jingzhe , Qu, Yishu , Wang, Jun , Okeke, Edith, Davwar, Pantong , Duguru, Mary, Nyam, David, Oyeleke, Ganiyat K. , Sulaimon, Akanmu A., Hawkins, Claudia , Badmos, Kabir, Gursel, Demirkan, Silas, Olugbenga A. , Kocherginsky, Masha , Sun, Zequn , Achenbach, Chad J. , Yang, Hushan , Sagay, Atiene S. , Roberts, Lewis R., Hou, Lifang , Roberts, Lewis R. , Yang, Hushan , Roberts, Lewis R , Zheng, Yinan , Hou, Lifang , Wang, Jun , Joyce, Brian , Odeghe, Emuobor , Lesi, Olufunmilayo , Imade, Godwin , Abdulkareem, Fatimah Biade , Wei, Jian‐Jun , Kim, Kwang‐Youn A. , Zhang, Xuehong , Ogunsola, Folasade Tolulope , Murphy, Robert L. , Roberts, Lewis R.

International Journal of Cancer | October 23, 2025 | Volume: 158 | Issue: 5 | Pages: 1281-1291

10.1002/ijc.70204 Get It

Abstract Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality globally, with particularly high burdens among people living with HIV (PLWH) in low‐resource settings like Nigeria. Effective early detection remains a major challenge due to limited access to imaging‐based surveillance and the low sensitivity of current biomarkers such as alpha‐fetoprotein (AFP). We conducted an epigenome‐wide association study (EWAS) of circulating cell‐free DNA (ccfDNA) methylation in a Nigerian cohort of HIV‐positive individuals ( n = 245), spanning HCC, cirrhosis (FibroScan ≥12.3 kPa), fibrosis (FibroScan ≥7.6 and <12.3 kPa), and HCC‐free without fibrosis (FibroScan <7.6 kPa) groups. Using random forest modeling, we developed and evaluated a ccfDNA methylation classifier (ccfDNAmRF) for HCC risk prediction. We identified 73 CpG sites significantly associated with HCC (false discovery rate <0.01). The ccfDNAmRF model demonstrated strong discriminatory power, achieving 100% sensitivity and 80%–91% specificity for distinguishing HCC from cirrhosis, fibrosis, and HCC‐free groups (area under the curve [AUC]: 92%–97%). Combining ccfDNA methylation risk scores with AFP further improved classification accuracy (AUC up to 98.5%). Notably, ccfDNA methylation patterns displayed clear dose–response relationships across the disease spectrum, supporting their utility for early‐stage detection and risk stratification. Our findings highlight the promise of ccfDNA methylation biomarkers as a non‐invasive, blood‐based screening tool for improving early identification of HCC cases among PLWH.
Defining standards for fluoroscopy in gastrointestinal endoscopy using Delphi methodology
Khalaf, Kareem , Pawlak, Katarzyna M. , Alkandari, Asma , Baron, Todd H. , Bechara, Robert , Binda, Cecilia , Chen, Yen‐I , Moura, Eduardo Guimarães Hourneaux de , Forbes, Nauzer , James, Paul, Martin, Harry , May, Gary R. , Mosko, Jeffrey D. , Oyeleke, Ganiyat K. , Petersen, Bret T. , Saxena, Payal , Sethi, Amrita , Sharaiha, Reem Z. , Tang, Raymond S. , Villarroel, Mariano , Hooft, Jeanin E. van , Renteln, Daniel von , Walsh, Catharine M. , Aberin, Tricia, Banavage, Dawn, Chen, Jowell Akina, Clancy, James, Drake, Heather, Im, Melanie, Low, Chooi Peng, Myszko, Alexandra, Navarro, Krista, Redman, Jessica, Reyes, Wayne, Weinstein, Faina, Na, Caleb, Tham, Daniel , He, Tony , Malipatil, Sharan B., Gimpaya, Nikko , Kundra, Arjun , Grover, Samir C. , Barkun, Alan N , Bechara, Robert , Binda, Cecilia , de Moura, Eduardo , Hassan, Cesare , Kahaleh, Michel , Sharaiha, Reem Z , Villarroel, Mariano , van Hooft, Jeanin E , Voermans, Rogier P , von Renteln, Daniel , Walsh, Catharine M , Gupta, Sunil , Fujiyoshi, Yusuke , Grover, Samir C , Causada Calo, Natalia S , Pawlak, Katarzyna M , Adler, Douglas G. , Barkun, Alan , Berzin, Tyler M. , Cai, Ming‐Yan , Carrara, Silvia , Fugazza, Alessandro , Hassan, Cesare , James, Paul D., Kahaleh, Michel , Maselli, Roberta , Repici, Alessandro , Spadaccini, Marco , Teshima, Christopher , Voermans, Rogier P. , Clancy, James, Reyes, Wayne, Gupta, Sunil , Mokhtar, Ahmed H., Gholami, Reza

Endoscopy International Open | October 7, 2024 | Volume: 12 | Issue: 11 | Pages: E1315-E1325

10.1055/a-2427-3893 Get It

Abstract Background and study aims Use of fluoroscopy in gastrointestinal endoscopy is an essential aid in advanced endoscopic interventions. However, it also raises concerns about radiation exposure. This study aimed to develop consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, prioritizing the safety and well-being of healthcare workers and patients. Methods A modified Delphi approach was employed to achieve consensus over three rounds of surveys. Proposed statements were generated in Round 1. In the second round, panelists rated potential statements on a 5-point scale, with consensus defined as ≥80% agreement. Statements were subsequently prioritized in Round 3, using a 1 (lowest priority) to 10 (highest priority) scale. Results Forty-six experts participated, consisting of 34 therapeutic endoscopists and 12 endoscopy nurses from six continents, with an overall 45.6% female representation (n = 21). Forty-three item statements were generated in the first round. Of these, 31 statements achieved consensus after the second round. These statements were categorized into General Considerations (n = 6), Education (n = 10), Pregnancy (n = 4), Family Planning (n = 2), Patient Safety (n = 4), and Staff Safety (n = 5). In the third round, accepted statements received mean priority scores ranging from 7.28 to 9.36, with 87.2% of statements rated as very high priority (mean score ≥ 9). Conclusions This study presents consensus-based statements for safe and effective use of fluoroscopy in gastrointestinal endoscopy, addressing the well-being of healthcare workers and patients. These consensus-based statements aim to mitigate risks associated with radiation exposure while maintaining benefits of fluoroscopy, ultimately promoting a culture of safety in healthcare settings.